Carbylan BioSurgery, Inc. Announces Appointment of President and CEO
Carbylan BioSurgery, Inc., a biotechnology company focused on the development and commercialization of advanced biomaterial-based joint therapies to treat pain associated with osteoarthritis, announced that it has appointed David M. Renzi as president, chief executive officer and member of the board of directors. The appointment of Mr. Renzi, a proven operational executive, signals a renewed focus on the Company’s long-term growth strategy and a dedication to product development and commercialization. The Company also announced that Samuel Lynch, D.M.D., D.M.Sc. has been appointed chairman of Carbylan’s board of directors.
Mr. Renzi has over 30 years of successful healthcare experience and spent the majority of this time with Ethicon and Ethicon Endosurgery, divisions of Johnson & Johnson. There he was given responsibility for numerous business disciplines including sales, sales management, marketing management and new procedure development. Most recently, Mr. Renzi was president and chief executive officer of Neomend, Inc., a company developing and commercializing hydrogels and surgical sealants for treating lung air leaks after surgical resection. Neomend was purchased by C.R. Bard in October 2012. Prior to Neomend, Mr. Renzi was executive vice president and chief commercial officer of Novacept, Inc. and SurgRx, Inc., both privately held venture-backed companies with successful exits in 2004 and 2008, respectively.
Other news from the department people
